GlassScriptPhysician profile
Aimi Ton
NPI 1588274526
$1,741.28
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,409 · 2022: $240 · 2023: $28.77 · 2024: $63.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $562.65 | 2021-2022 | |
| Amgen INC. | $223.27 | 2021 | |
| Abbvie INC. | $151.04 | 2021-2023 | |
| Dexcom, INC. | $107.47 | 2022 | |
| Lilly USA, LLC | $106.70 | 2021 | |
| Novo Nordisk INC | $83.07 | 2021 | |
| Nestle Healthcare Nutrition INC. | $74.91 | 2021 | |
| Amarin Pharma, INC. | $72.25 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $58.32 | 2021 | |
| Redhill Biopharma INC. | $47.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $44.88 | 2021 | |
| Merck Sharp & Dohme LLC | $43.63 | 2021 | |
| Glaxosmithkline, LLC. | $24.89 | 2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $23.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.90 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.89 | 2024 | Thinprep 2000 Processor, Aptima |
| Dermira, INC. | $20.73 | 2021 | |
| Genentech USA, INC. | $20.38 | 2021 | |
| Pfizer INC. | $16.59 | 2024 | |
| Gilead Sciences, INC. | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimi Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.